RE:Shelf Registration - Bad OmenCarlitto,
You and I both know comparing quipt to early stage biotech companies is a poor comparison
Many of these biotech names have:
Negative Free Cashflows
Zero revenue growth
single-threaded product with long pre-launch cycles
Quipt is none of this. Yes - there COULD be shareholder dilution and I'm not entirely pleased about the additional stock options and RSU's earlier in the year, but if this helps with employee retention I'll take it. And If this shelf will help with identifying and acquiring accretive orgs, we should be all for it.
Let's remember - when they did their last placement the stock jumped once acquisitions started rolling in.